<![CDATA[Increased blood sugar levels indicate a metabolic disease known as diabetes mellitus (DM). DM is often accompanied by hypertension. Antidiabetic therapy that can be used is metformin, either monotherapy or combined with other drugs such as glimepiride. This study aimed to analyze the risk of heart disease based on creatine phosphokinase (CPK) in patients with type 2 DM and hypertension who are taking metformin and a combination of metformin and glimepiride. We conducted an analytic observational using a cross-sectional design and applied a purposive sampling technique. The study subjects were type 2 DM patients with hypertension who met the inclusion criteria. The data analysis used univariate analysis, Mann-Whitney, and Fisher’s. The results showed that women aged 60-75 years old with uncontrolled FBS, duration of DM < 5 years, and high CPL level were dominated by our respondents. We found that there was no difference in CPK values (p=0.916), and there was no relationship between the use of metformin monotherapy or the combination of metformin and glimepiride on the risk of heart disease in type 2 DM patients with hypertension (p=0.693). In conclusion, metformin consumption in type 2 DM patients has no significant association with heart disease risk.]]>
Copyrights © 2024
